Skip to content

Antidepressant pharmacology

TL;DR — Antidepressants produce modest average acute benefit, substantial individual variation, and meaningful relapse prevention after response. In 522 trials (116,477 participants), all 21 studied drugs outperformed placebo for acute response, with odds ratios 1.37–2.13 (Cipriani 2018, PMID 29477251). Between-drug efficacy differences are smaller than differences in adverse effects, interactions, withdrawal burden, and patient preference. Continuation after response reduced relapse from 41% to 18% in an older systematic review (Geddes 2003, PMID 12606176). Stopping can cause withdrawal—often dizziness, sensory symptoms, insomnia, anxiety, and flu-like symptoms—which must be distinguished from relapse (Davies 2019, PMID 30292574).

Classes and decision variables

Class Examples Main pharmacology Common limiting effects
SSRI sertraline, escitalopram, fluoxetine serotonin transporter inhibition sexual dysfunction, GI symptoms, activation, withdrawal
SNRI venlafaxine, duloxetine serotonin/noradrenaline reuptake inhibition nausea, blood-pressure effects, withdrawal
Atypical bupropion, mirtazapine dopamine/noradrenaline or receptor actions activation; or sedation/weight gain
TCA amitriptyline, clomipramine monoamine reuptake plus receptor/channel effects anticholinergic effects, orthostasis, overdose toxicity
MAOI phenelzine, tranylcypromine monoamine oxidase inhibition interactions, dietary restrictions, orthostasis
Multimodal vortioxetine transporter plus receptor actions nausea, sexual effects still possible

Mechanism labels do not predict response reliably. Selection usually optimizes prior response, symptom pattern, comorbidity, interactions, overdose risk, reproductive context, cost, and adverse-effect preference.

Acute efficacy

Cipriani's network meta-analysis found all 21 antidepressants more efficacious than placebo; ORs ranged from 2.13 for amitriptyline to 1.37 for reboxetine (Cipriani 2018, PMID 29477251). Rankings combine direct and indirect comparisons and apply to trial populations, not an individual patient's probability.

Question Best answer
Do antidepressants beat placebo on average? Yes, in adult acute MDD trials (Cipriani 2018, PMID 29477251)
Is one drug best for everyone? No
Are mean effects large? Generally modest; interpretation is contested
Does response prove monoamine deficiency? No
Does early non-response justify immediate stopping? Not automatically; dose, adherence, time, and trajectory matter

Escitalopram-focused synthesis finds broadly similar efficacy to other agents with some tolerability advantages, illustrating why acceptability often drives first-line choice (Yin 2023, PMID 38001423). Gastrointestinal adverse effects differ by agent and contribute to early dropout (Oliva 2021, PMID 33549697).

Combination and sequencing

Combining antidepressants can improve acute outcomes in selected comparisons, especially reuptake inhibitors combined with alpha-2 antagonists, but heterogeneity and tolerability constrain routine use (Henssler 2022, PMID 35171215). STAR*D found diminishing remission across treatment steps and greater relapse among those requiring more steps (Rush 2006, PMID 17074942); its cumulative remission interpretation is disputed (Pigott 2023, PMID 37491091).

Continuation and maintenance

After acute response, discontinuing into placebo increased relapse: pooled relapse was 41% on placebo versus 18% continuing antidepressant in a systematic review (Geddes 2003, PMID 12606176). A newer maintenance network meta-analysis supports continued efficacy across agents while emphasizing trial enrichment and withdrawal-design limitations (Kishi 2023, PMID 36253442).

Phase Goal Typical evidence question
Acute response/remission drug vs placebo over ~6–12 weeks
Continuation prevent return of index episode continue vs stop after response
Maintenance prevent new episodes longer-term recurrence prevention

Relapse-prevention trials often randomize responders, enriching for benefit and tolerability. Abrupt substitution with placebo can also misclassify withdrawal as relapse.

Adverse effects

Domain Higher-risk patterns Mitigation principle
Sexual function many serotonergic agents ask directly; baseline assessment; shared decisions
Weight/metabolic varies; mirtazapine often problematic monitor trajectory, not one measurement
Activation/insomnia activating drugs, early treatment timing, slower titration, reassess bipolarity
Sedation mirtazapine, TCAs driving/fall risk and timing
BP/heart rate SNRIs, TCAs baseline risk and monitoring
Hyponatremia/bleeding serotonergic drugs in susceptible patients medication and medical-risk review
Overdose toxicity TCAs and some others suicide-risk-informed quantities

Sexual dysfunction is underdetected unless asked about explicitly and can persist while medication continues; evidence and management options remain uneven (Rothmore 2020, PMID 32172535). Serotonin syndrome is an uncommon but potentially severe toxidrome, especially with combinations; clinical reviews distinguish it from ordinary serotonergic adverse effects (Marks 2023, PMID 37495413).

Withdrawal versus relapse

Withdrawal can begin soon after dose reduction, often includes neurological or flu-like phenomena atypical of relapse, and may improve rapidly with reinstatement. Relapse more often reproduces the person's depressive syndrome and may emerge later. Neither timing nor symptoms are perfectly specific.

Davies and colleagues reported high incidence and sometimes prolonged symptoms but also substantial heterogeneity and risk of bias across studies (Davies 2019, PMID 30292574). This uncertainty supports individualized, proportionate tapering rather than a universal schedule.

Comparative benefit–harm deepening

Drug selection is usually a multi-outcome decision. Average acute efficacy differences are narrower than many differences in withdrawal liability, sexual function, sleep, weight, cardiovascular effects, interactions, and overdose toxicity.

Decision Evidence direction Residual uncertainty
Continue after remission? Discontinuation meta-analysis favors continuation for relapse prevention Responder enrichment and withdrawal masquerading as relapse inflate apparent maintenance benefit
Choose by weight effect? Large target-trial emulation found clinically relevant between-drug weight differences Confounding and short follow-up limit long-term causal ranking
Treat early weight gain as noise? METADAP cohorts linked early gain to later gain and metabolic syndrome Prediction does not establish that switching improves net outcome
Rank drugs by sleep effects? Dose-effect network evidence shows heterogeneous insomnia/somnolence profiles Trial adverse-event elicitation is inconsistent
Estimate withdrawal frequency? Randomized and observational syntheses disagree materially Definitions, taper speed, duration of exposure, and nocebo differ

Sexual adverse effects remain underascertained in spontaneous reporting, while persistent post-treatment syndromes have uncertain incidence. Harms should therefore be elicited prospectively and reported with denominators rather than described as merely “common” or “rare.”

Additional live-search evidence ledger

The records below were added after full PubMed E-utilities retrieval on 2026-08-30. The ledger states the evidentiary role of each record and preserves the design limitation that should travel with its citation.

  • Petimar J 2024 — Medication-Induced Weight Change Across Common Antidepressant Treatments : A Target Trial Emulation Study. Primary or secondary empirical evidence; interpretation should follow its design and comparator rather than the headline alone. (Petimar J 2024, PMID 38950403)

  • Wartko PD 2021 — Maternal Gestational Weight Gain in Relation to Antidepressant Continuation in Pregnancy. Primary or secondary empirical evidence; interpretation should follow its design and comparator rather than the headline alone. (Wartko PD 2021, PMID 32604448)

  • van Wijk EJC 2026 — Gestational weight gain and postpartum weight retention: What is the role of perinatal antidepressant use? Primary or secondary empirical evidence; interpretation should follow its design and comparator rather than the headline alone. (van Wijk EJC 2026, PMID 41161536)

  • Lassale C 2024 — Trajectories of antidepressant use and 6-year change in body weight: a prospective population-based cohort study. Longitudinal observational evidence; temporal ordering improves inference but residual confounding remains. (Lassale C 2024, PMID 39777198)

  • Nguyen C 2018 — Weight gain changes in patients with aripiprazole monotherapy compared with aripiprazole-antidepressant polypharmacy in an outpatient sample. Primary or secondary empirical evidence; interpretation should follow its design and comparator rather than the headline alone. (Nguyen C 2018, PMID 29215304)

  • El Asmar K 2018 — Early weight gain predicts later metabolic syndrome in depressed patients treated with antidepressants: Findings from the METADAP cohort. Longitudinal observational evidence; temporal ordering improves inference but residual confounding remains. (El Asmar K 2018, PMID 30390577)

  • Asmar KE 2018 — Early weight gain predicts later weight gain in depressed patients treated with antidepressants: Findings from the METADAP cohort. Longitudinal observational evidence; temporal ordering improves inference but residual confounding remains. (Asmar KE 2018, PMID 30092445)

  • Ishikawa S 2025 — Assessment of factors associated with antipsychotic-induced weight gain: A nationwide cohort study. Longitudinal observational evidence; temporal ordering improves inference but residual confounding remains. (Ishikawa S 2025, PMID 39725015)

  • Kivimäki M 2010 — Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. Primary or secondary empirical evidence; interpretation should follow its design and comparator rather than the headline alone. (Kivimäki M 2010, PMID 20823343)

  • Serretti A 2026 — Transdiagnostic medication-associated weight gain across five effectiveness trials: a harmonized longitudinal cohort analysis of antipsychotics, antidepressants, and mood stabilizers. Longitudinal observational evidence; temporal ordering improves inference but residual confounding remains. (Serretti A 2026, PMID 42492718)

  • Xie M 2026 — Post-SSRI Sexual Dysfunction (PSSD): A comprehensive review of epidemiology, pathophysiology, and clinical management. Review-level synthesis; conclusions inherit limitations of the underlying designs. (Xie M 2026, PMID 42430418)

  • Tarchi L 2023 — Selective serotonin reuptake inhibitors, post-treatment sexual dysfunction and persistent genital arousal disorder: A systematic review. Systematic review; useful for mapping consistency and gaps, not automatically a pooled causal estimate. (Tarchi L 2023, PMID 37294623)

  • Brugi S 2026 — The use of patient-reported outcome measures in assessing the prevalence and tolerance of SSRI-related sexual dysfunction: a systematic review. Systematic review; useful for mapping consistency and gaps, not automatically a pooled causal estimate. (Brugi S 2026, PMID 42466890)

  • Pereira VM 2014 — Bupropion in the depression-related sexual dysfunction: a systematic review. Systematic review; useful for mapping consistency and gaps, not automatically a pooled causal estimate. (Pereira VM 2014, PMID 24923342)

Open questions

  • Which baseline features predict differential benefit rather than general prognosis (Cipriani 2018, PMID 29477251)?
  • How much relapse-prevention benefit is inflated by enriched designs and withdrawal confounding (Kishi 2023, PMID 36253442)?
  • What taper shapes minimize severe withdrawal after long exposure (Davies 2019, PMID 30292574)?
  • Which combination strategies justify added adverse effects (Henssler 2022, PMID 35171215)?

References

  1. Cipriani A, et al. Comparative efficacy and acceptability of 21 antidepressant drugs. Lancet. 2018. PMID 29477251
  2. Geddes JR, et al. Relapse prevention with antidepressant drug treatment in depressive disorders. Lancet. 2003. PMID 12606176
  3. Kishi T, et al. Antidepressants in the maintenance phase: systematic review and network meta-analysis. Molecular Psychiatry. 2023. PMID 36253442
  4. Yin J, et al. Escitalopram versus other antidepressive agents for MDD. BMC Psychiatry. 2023. PMID 38001423
  5. Oliva V, et al. Gastrointestinal side effects associated with antidepressant treatments. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2021. PMID 33549697
  6. Henssler J, et al. Combining antidepressants versus monotherapy. JAMA Psychiatry. 2022. PMID 35171215
  7. Rush AJ, et al. Acute and longer-term outcomes in STAR*D. American Journal of Psychiatry. 2006. PMID 17074942
  8. Pigott HE, et al. Protocol-faithful reanalysis of STAR*D. BMJ Open. 2023. PMID 37491091
  9. Davies J, Read J. Incidence, severity and duration of antidepressant withdrawal effects. Addictive Behaviors. 2019. PMID 30292574
  10. Rothmore J. Antidepressant-induced sexual dysfunction. Medical Journal of Australia. 2020. PMID 32172535
  11. Marks S. Antidepressants, sexual side-effects, post-SSRI sexual dysfunction, and serotonin syndrome. British Journal of Nursing. 2023. PMID 37495413
  12. Petimar J, et al. Medication-Induced Weight Change Across Common Antidepressant Treatments : A Target Trial Emulation Study. Annals of internal medicine. 2024;177:993-1003. PMID 38950403
  13. Wartko PD, et al. Maternal Gestational Weight Gain in Relation to Antidepressant Continuation in Pregnancy. American journal of perinatology. 2021;38:1442-1452. PMID 32604448
  14. van Wijk EJC, et al. Gestational weight gain and postpartum weight retention: What is the role of perinatal antidepressant use? Journal of affective disorders. 2026;394:120521. PMID 41161536
  15. Lassale C, et al. Trajectories of antidepressant use and 6-year change in body weight: a prospective population-based cohort study. Frontiers in psychiatry. 2024;15:1464898. PMID 39777198
  16. Nguyen C, et al. Weight gain changes in patients with aripiprazole monotherapy compared with aripiprazole-antidepressant polypharmacy in an outpatient sample. Journal of psychopharmacology (Oxford, England). 2018;32:423-429. PMID 29215304
  17. El Asmar K, et al. Early weight gain predicts later metabolic syndrome in depressed patients treated with antidepressants: Findings from the METADAP cohort. Journal of psychiatric research. 2018;107:120-127. PMID 30390577
  18. Asmar KE, et al. Early weight gain predicts later weight gain in depressed patients treated with antidepressants: Findings from the METADAP cohort. Journal of affective disorders. 2018;241:22-28. PMID 30092445
  19. Ishikawa S, et al. Assessment of factors associated with antipsychotic-induced weight gain: A nationwide cohort study. Progress in neuro-psychopharmacology & biological psychiatry. 2025;136:111231. PMID 39725015
  20. Kivimäki M, et al. Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. Diabetes care. 2010;33:2611-6. PMID 20823343
  21. Serretti A. Transdiagnostic medication-associated weight gain across five effectiveness trials: a harmonized longitudinal cohort analysis of antipsychotics, antidepressants, and mood stabilizers. Progress in neuro-psychopharmacology & biological psychiatry. 2026;149:111854. PMID 42492718
  22. Xie M, et al. Post-SSRI Sexual Dysfunction (PSSD): A comprehensive review of epidemiology, pathophysiology, and clinical management. The International journal of risk & safety in medicine. 2026:9246479261468499. PMID 42430418
  23. Tarchi L, et al. Selective serotonin reuptake inhibitors, post-treatment sexual dysfunction and persistent genital arousal disorder: A systematic review. Pharmacoepidemiology and drug safety. 2023;32:1053-1067. PMID 37294623
  24. Brugi S, et al. The use of patient-reported outcome measures in assessing the prevalence and tolerance of SSRI-related sexual dysfunction: a systematic review. The journal of sexual medicine. 2026;23:qdag218. PMID 42466890
  25. Pereira VM, et al. Bupropion in the depression-related sexual dysfunction: a systematic review. CNS & neurological disorders drug targets. 2014;13:1079-88. PMID 24923342